drug discovery News
-
Closing the Loop on AI in Drug Discovery.
Attending SMi Group's AI in Drug Discovery? Be sure to check out our very own Irene Choi, PhD, who will be participating in an exciting panel -- Closing the Loop on AI in Drug Discovery. https://www.linkedin.com/feed/update/urn:li:activity:6909129239237709824/ ...
-
Sirenas Receives Research Grant Totaling $1.68 M To Accelerate Its Drug Discovery Technology, ATLANTIS™
Sirenas, LLC ("Sirenas"), a biotechnology company harnessing computational approaches to discover therapeutics derived from nature's chemistry, announced that it has received a new grant from the Bill & Melinda Gates Foundation to advance ATLANTIS™, the company's proprietary drug discovery technology. With today's announcement, Sirenas has now received two research grant awards from ...
By Sirenas
-
Creative Biostructure Drug Discovery Established MagHelixTM CADD Platform
Creative Biostructure Drug Discovery, a sub-brand of Creative Biostructure, whose mission is to accelerate the preclinical development of innovative drugs through structural insight, recently established a MagHelix™ CADD Platform, a comprehensive platform for new drug discovery that integrates a variety of computer applications. Computer-aided drug design (CADD) has penetrated into all ...
-
BOC Sciences to Exhibit at Drug Discovery Chemistry 2024, Booth #117
BOC Sciences, a tech-driven company, is delighted to announce that its team will be participating in the prestigious Drug Discovery Chemistry (DDC) conference in April 2024. The company will be situated at booth #117, showcasing its quality chemical materials and advanced technologies. DDC is an annual event that gathers researchers, scientists, and experts from across the globe who are involved ...
By BOC Sciences
-
European Biotech & Pharma Virtual Partnering Conference 2021
We are looking forward to the European Biotech & Pharma Virtual Partnering Conference, September 27-30, 2021. During the conference, we meet Japanese pharma companies and will show how PharmAI’s ground-breaking technology helps to accelerate the drug discovery process. ...
By PharmAI GmbH
-
Orion Shares New Data on its Latest Best-in-Class Drug Candidate
Orion Biotechnology Canada Ltd, a drug discovery and development company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting important new data at both LSX World Congress and TIDES USA 2022 conference, taking place this week – May 10-12, 2022. Dr. Oliver Hartley, Orion’s Vice-President Drug Discovery, will present ...
-
Creative Biostructure Provides Solutions for Drug Design with Structure-based Drug Design Platform
Creative Biostructure Drug Discovery, a sub-brand of Creative Biostructure that applies its expertise in structural biology and membrane proteins to the drug discovery process, has developed MagHelix™ Structural Biology and SBDD Platform that covers all the mainstream technologies needed to successfully determine the 3D structure of biological macromolecules. Structure-based drug design ...
-
Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset
Ardigen, one of the world’s leading artificial intelligence (AI) companies advancing precision medicine, has announced that it is supporting the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) Consortium with its technology and expertise. The consortium of 10 leading pharmaceutical companies and two non-profit research organizations including the Broad Institute of MIT ...
By Ardigen
-
Neotx Acquires Interx, ADDS World Class Discovery Arm
NeoTX announced today the acquisition of InterX. InterX, is a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel Prize Laureate Prof Michael Levitt’s discoveries. These tools allow a detailed quantum mechanical process assessment of biochemical interactions resulting in faster, ...
By InterX
-
Orion Biotechnology & Peptilogics Enter Strategic Research Collaboration to Enable AI-driven GPCR drug discovery
Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors (GPCRs), and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to ...
-
Optibrium appoints Ian Smith as Chief Technology Officer
New role will lead technology development as the Company continues to scale team and global business operations. The appointment of former Merck, Sharp and Dohme (MSD) Director of R&D Analytics supports continued innovation of Optibrium’s AI drug discovery software Optibrium a leading developer of software and AI solutions for drug discovery, today announced the appointment of Ian ...
-
The `Network for Pharma Solutions` (NetPhaSol) starts campaign for networking and cooperation
NetPhaSol, the nationwide network of 30 companies and 20 research institutions covering the entire value chain in drug discovery and development, is launching its campaign for networking and cooperation. Are you looking for qualified partner for your project? Are you looking for special expertise for a technological solution? Then NetPhaSol is the right partner for you. Access to the network is ...
-
Iktos Announces a Collaboration With Ono in Artificial Intelligence for New Drug Design
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design today announced a collaboration agreement with Ono Pharmaceuticals Co., Ltd., a leading pharmaceutical company based in Japan with a focus on innovative medicines dedicated to the fight against disease and pain. Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling ...
By Iktos
-
Nathan Brown joins Healx as Director of Digital Chemistry
Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, is proud to announce that world-renowned computational drug discovery expert, Nathan Brown, has joined the team as Director of Digital Chemistry. Nathan joins from BenevolentAI, where he led the Cheminformatics team and was responsible for the research and development of new and ...
By Healx Ltd.
-
Optibrium strengthens global AI drug discovery software operations with three key appointments
Michelle Harrison appointed as Head of Strategic Marketing; Chris Khoury and Imran Ghauri join to boost Optibrium’s business development team. UK and US-based appointments with proven AI and life science expertise will support the next phase of commercial growth for Optibrium’s computational drug discovery technologies. Optibrium, a leading developer of software and artificial ...
-
Healx launches AI-powered indication expansion partnership with Ono Pharmaceutical Co. Ltd.
Healx, the AI-powered, patient-inspired technology company pioneering the next generation of drug discovery, today announced an exciting partnership with Ono Pharmaceutical Co., Ltd., one of Japan’s largest pharmaceutical companies and a global leader in the field of R&D-orientated drug discovery. The collaboration will leverage Healx’s innovative indication expansion technology ...
By Healx Ltd.
-
Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy
Beijing Tide Pharmaceutical Co., Ltd. (Tide), a subsidiary of Sino Biopharmaceutical Limited, and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines, announced today that they are entering a collaboration, applying artificial intelligence (AI) technology to drug discovery, to jointly accelerate the process for multiple types of cancer treatment. ...
-
NuMedii Advances IPF Personalized Medicine with New Advisory Board to Guide AI Approach
NuMedii is advancing the field of personalized medicine for idiopathic pulmonary fibrosis (IPF) by creating a new advisory board that includes some of the world’s leading specialists in interstitial lung disease to guide a new approach to drug discovery based on artificial intelligence (AI). The California-based company has been exploring the potential of big data and AI since 2010 to ...
-
HTI receives $1M National Science Foundation SBIR Phase II award for CryoDiscovery: A Cryo-EM Automation and Intelligence Platform for Drug Discovery
The NSF has recognized HTI’s progress applying AI/ML to cryo-EM image processing with a $1M SBIR Phase II grant award for CryoDiscovery(™), a cryo-EM automation and intelligence platform for drug discovery. A Phase I award was earlier used to successfully build and test a platform prototype, while the Phase II award will play a key role in its commercialization. HTI’s Chief ...
-
Natural Product Identification and Production for Drug Discovery Now Available at Creative Biostructure
Creative Biostructure Drug Discovery, a sub-brand of Creative Biostructure, established to apply its expertise in structural biology and membrane proteins to drug discovery process, now offers natural product identification and production service for drug discovery from natural products. Natural products are the source of chemical diversity and are the ideal starting point for most small ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you